Inicio>>Denosumab

Denosumab (Synonyms: D03684; Denosumab; Denosumab (usan))

Catalog No.GC19535

Denosumab es de todos los anticuerpos monoclonales humanos IgG2.

Products are for research use only. Not for human use. We do not sell to patients.

Denosumab Chemical Structure

Cas No.: 615258-40-7

Tamaño Precio Disponibilidad Cantidad
1mg
165,00 $
Disponible
5mg
495,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Denosumab is a fully human IgG2 monovlonal antibody that binds human RANKL with a high affinity, exhibiting a dissociation equilibrium binding constant (Kd) of 3 pM as determined by immunoaffinity exclusion chromatography. Denosumab binds both soluble and membrane-bound primate RANKL but fails to recognize mouse or rat RANKL- a finding that is supported by sequence analysis of RANKL from diverse mammalian species. [2]

Initial screening of RANKL antibodies for in vivo bioactivity leveraged the crossreactivity of Denosumab with cynomolgus RANKL. Single-dose testing in cynomolgus monkeys revealed that infrequent dosing regimens in humans may be possible. The primary in vivo testing in primates accelerated the developmental timeframe of this molecule, which normally would have been preceded by extensive testing in animal models of bone loss in which recombinant OPG was active. [2]

Denosumab does not bind to other TNF family members, such as TRAIL, CD40 ligand (CD40L), TNFα and THFβ. Denosumab binds to the DE loop region of human RANKL, which is one of the surface loop structures that forms contacts with RANK on responding cells. Owing to the different terminology used for the loop regions, the human DE loop region corresponds to the CD loop regions of the murine RANKL structure. Both Denosumab and OPG-Fc bind to soluble or membrane-bound human RANKL and block it from binding to and oligomerizing its receptor, RANK. Denosumab, however, is more specific than human OPG-Fc because Denosumab recognizes only human and non-human primate RANKL, in contrast to OPG, which also binds to mouse and rat RANKL as well as TRAIL. [1,2]

References:
[1]. Feng, Qi et al. Denosumab inhibits MCF-7 cell line-induced spontaneous osteoclastogenesis via the RANKL/MALAT1/miR-124 axis.” Translational cancer research vol. 9,4 (2020): 2482-2491.
[2]. Lacey, David L et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of Denosumab. Nature reviews. Drug discovery vol. 11,5 (2012): 401-19.

Reseñas

Review for Denosumab

Average Rating: 5 ★★★★★ (Based on Reviews and 8 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Denosumab

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.